title: Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
abstract: The identification of women with early-stage breast cancer who will develop distant metastasis may improve clinical management. The transcriptional regulator Enhancer of Zeste-2 (EZH2) is overexpressed in invasive breast carcinoma compared with benign breast tissues, with maximal expression in breast cancer metastasis. In this article, our purpose was to investigate the performance of EZH2 protein detection as a predictor of metastasis in women with early-stage breast cancer, which is unknown. We developed a cohort of 480 women with stage I-IIA breast cancer diagnosed between 1996 and 2002 and recorded detailed sociodemographic, clinical, and pathological information. Tumors were histologically characterized and arrayed in tissue microarrays containing 1,443 samples. The nuclear EZH2 expression was investigated by immunohistochemistry and was scored as 1-2 (negative and weak) or 3-4 (moderate and strong) using a validated scoring schema. Scores 1-2 were considered low EZH2; scores 3-4 were considered high EZH2. In this study, we found that after a median follow up of 9 years (range 0.04-14.5 years) 46 of 480 patients (9.6%) developed distant metastasis. High EZH2 was associated with larger size, high histological grade, negative hormone receptors, and first degree family history of breast and/or ovarian carcinoma. While EZH2 could not predict survival in the entire cohort, high EZH2 was a predictor of disease-specific survival in patients with early-stage disease and first degree family history (log rank P value 0.05). Importantly, in this group of patients, high EZH2 was an independent predictor of distant metastasis up to 15 years after primary carcinoma diagnosis (hazard ratio 6.58, 95% CI: 1.40-30.89, P = 0.016) providing survival information above and beyond currently used prognosticators. In conclusion, EZH2 may be a useful biomarker of long-term metastatic risk in women with familial early-stage breast cancer, and warrant further validation studies.
authors: Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.
authors: Sharon Hensley
authors: SH
authors: Alford
authors: Katherine
authors: K
authors: Toy
authors: Sofia D
authors: SD
authors: Merajver
authors: Celina G
authors: CG
authors: Kleer
references: Neoplasia. 2003 Nov-Dec;5(6):481-8
references: 14965441
references: Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:15-24
references: 19082929
references: Trends Mol Med. 2004 Oct;10(10):500-7
references: 15464450
references: Cancer Sci. 2006 Jun;97(6):484-91
references: 16734726
references: Mol Cell Biol. 2002 Sep;22(17):6070-8
references: 12167701
references: Cell. 1991 May 31;65(5):753-63
references: 1904009
references: J Clin Oncol. 2006 Jan 10;24(2):268-73
references: 16330673
references: Br J Surg. 1986 Aug;73(8):604-6
references: 3742167
references: Cancer Res. 2006 Oct 1;66(19):9352-5
references: 17018586
references: Neoplasia. 2004 Nov-Dec;6(6):736-43
references: 15720799
references: EMBO J. 1997 Jun 2;16(11):3219-32
references: 9214638
references: J Clin Oncol. 1998 Jun;16(6):2045-51
references: 9626202
references: Br J Cancer. 2005 May 9;92(9):1754-8
references: 15856046
references: Oncogene. 2009 Feb 12;28(6):843-53
references: 19079346
references: EMBO J. 2003 Oct 15;22(20):5323-35
references: 14532106
references: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
references: 14500907
references: Biochim Biophys Acta. 1999 Oct 6;1447(1):1-16
references: 10500238
references: Breast Cancer Res Treat. 2006 Nov;100(2):229-35
references: 16932852
references: Cancer Res. 2011 Mar 15;71(6):2360-70
references: 21406404
references: Clin Cancer Res. 2006 Feb 15;12(4):1168-74
references: 16489070
references: Breast Cancer Res. 2009;11(4):R63
references: 19709408
references: Annu Rev Genet. 2004;38:413-43
references: 15568982
references: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8570-6
references: 16361539
references: Nature. 2002 Oct 10;419(6907):624-9
references: 12374981
references: Neoplasia. 2005 Nov;7(11):1011-9
references: 16331887
references: Breast Cancer Res. 2008;10(6):R109
references: 19099573
references: Oncogene. 2008 Dec 11;27(58):7274-84
references: 18806826
references: Mod Pathol. 2008 May;21 Suppl 2:S8-S15
references: 18437174
references: Cancer Cell. 2011 Jan 18;19(1):86-100
references: 21215703
references: Nature. 2006 May 18;441(7091):349-53
references: 16625203
references: Urol Int. 2005;75(3):252-7
references: 16215315
references: Cancer Res. 2006 Apr 15;66(8):4095-9
references: 16618729
references: Int J Mol Med. 2005 Aug;16(2):349-53
references: 16012774